S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
Log in
NASDAQ:BNTX

BioNTech Stock Forecast, Price & News

$110.61
+2.17 (+2.00 %)
(As of 01/25/2021 05:08 PM ET)
Add
Compare
Today's Range
$105.14
Now: $110.61▼
$110.98
50-Day Range
$81.52
MA: $103.68▼
$129.54
52-Week Range
$28.00
Now: $110.61▼
$131.00
Volume2.88 million shs
Average Volume2.72 million shs
Market Capitalization$25.03 billion
P/E RatioN/A
Dividend YieldN/A
Beta-1.74
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in developing FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/II trial for prostate cancer; BNT113, which is in Phase I trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116, which is in preclinical trail for non-small cell lung cancer. It also develops neo-antigen specific immunotherapies, such as RO7198457, which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT152 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT212 for pancreatic and other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops MVT-5873, an IgG1 monoclonal antibody, which is in Phase I/II clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Eli Lilly and Company; Bayer AG; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; Regeneron Pharmaceuticals, Inc.; and InstaDeep Ltd. The company was founded in 2008 and is headquartered in Mainz, Germany.

MarketRank™

Overall MarketRank™

1.11 out of 5 stars

Medical Sector

908th out of 1,922 stocks

Biological Products, Except Diagnostic Industry

121st out of 177 stocks

Analyst Opinion: 2.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BNTX
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.biontech.de
Phone49-61-31908-40
Employees1,310
Year FoundedN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio4.07
Quick Ratio4.02

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$121.63 million
Price / Sales205.76
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.44 per share
Price / Book45.33

Profitability

EPS (Most Recent Fiscal Year)($0.95)
Net Income$-200,540,000.00
Net Margins-250.12%
Return on Equity-66.72%
Return on Assets-41.73%

Miscellaneous

Outstanding Shares226,262,000
Market Cap$25.03 billion
Next Earnings Date3/30/2021 (Estimated)
OptionableNot Optionable
$110.61
+2.17 (+2.00 %)
(As of 01/25/2021 05:08 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BNTX News and Ratings via Email

Sign-up to receive the latest news and ratings for BNTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











BioNTech (NASDAQ:BNTX) Frequently Asked Questions

How has BioNTech's stock been impacted by COVID-19?

BioNTech's stock was trading at $32.17 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BNTX stock has increased by 243.8% and is now trading at $110.61.
View which stocks have been most impacted by COVID-19.

Is BioNTech a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last twelve months. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BioNTech stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BNTX, but not buy additional shares or sell existing shares.
View analyst ratings for BioNTech or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than BioNTech?

Wall Street analysts have given BioNTech a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but BioNTech wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Ugur Sahin's approval rating as BioNTech's CEO?

10 employees have rated BioNTech CEO Ugur Sahin on Glassdoor.com. Ugur Sahin has an approval rating of 89% among BioNTech's employees.

When is BioNTech's next earnings date?

BioNTech is scheduled to release its next quarterly earnings announcement on Tuesday, March 30th 2021.
View our earnings forecast for BioNTech.

How were BioNTech's earnings last quarter?

BioNTech SE (NASDAQ:BNTX) issued its quarterly earnings results on Sunday, November, 15th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.37) by $0.51. The business had revenue of $67.50 million for the quarter, compared to analyst estimates of $50.53 million. BioNTech had a negative trailing twelve-month return on equity of 66.72% and a negative net margin of 250.12%. The business's revenue for the quarter was up 135.2% on a year-over-year basis.
View BioNTech's earnings history.

What price target have analysts set for BNTX?

7 brokerages have issued 12-month price targets for BioNTech's shares. Their forecasts range from $62.00 to $130.00. On average, they expect BioNTech's share price to reach $101.63 in the next year. This suggests that the stock has a possible downside of 8.1%.
View analysts' price targets for BioNTech or view Wall Street analyst' top-rated stocks.

Who are some of BioNTech's key competitors?

Some companies that are related to BioNTech include Gilead Sciences (GILD), Moderna (MRNA), Biogen (BIIB), Seagen (SGEN), Novozymes A/S (NVZMY), argenx (ARGX), Bio-Techne (TECH), CRISPR Therapeutics (CRSP), QIAGEN (QGEN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Denali Therapeutics (DNLI), Twist Bioscience (TWST), Adaptive Biotechnologies (ADPT) and Fate Therapeutics (FATE).
View all of BNTX's competitors.

What other stocks do shareholders of BioNTech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioNTech investors own include Moderna (MRNA), Pfizer (PFE), Inovio Pharmaceuticals (INO), Tesla (TSLA), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Zoom Video Communications (ZM) and Advanced Micro Devices (AMD).

Who are BioNTech's key executives?

BioNTech's management team includes the following people:
  • Prof. Ugur Sahin M.D., Co-Founder, CEO & Member of Management Board (Age 54)
  • Dr. Sierk Poetting Ph.D., CFO, MD, COO & Member of Management Board (Age 46)
  • Mr. Sean Marett, Chief Bus. Officer, Chief Commercial Officer & Member of Management Board (Age 54)
  • Dr. Özlem Türeci, Chief Medical Officer & Member of Management Board (Age 52)
  • Prof. Christoph Hubert Huber, Co-Founder & Member of Supervisory Board (Age 75)
  • Mr. Ryan Richardson, Chief Strategy Officer, MD & Member of Management Board (Age 40)
  • Sylke Maas, VP of Investor Relations and Bus. Strategy
  • Dr. James Timothy Patrick Ryan Ph.D., VP of Legal & Intellectual Property
  • Michael Boehler, MD & Head of Global External Communications
  • Katalin Kariko, Sr. VP & Head of RNA Protein Replacement

When did BioNTech IPO?

(BNTX) raised $251 million in an initial public offering on Thursday, October 10th 2019. The company issued 13,200,000 shares at $18.00-$20.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink served as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers.

What is BioNTech's stock symbol?

BioNTech trades on the NASDAQ under the ticker symbol "BNTX."

Who are BioNTech's major shareholders?

BioNTech's stock is owned by a variety of retail and institutional investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.04%), Kestra Advisory Services LLC (0.00%) and First Midwest Bank Trust Division (0.00%).

Which major investors are selling BioNTech stock?

BNTX stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A..

Which major investors are buying BioNTech stock?

BNTX stock was acquired by a variety of institutional investors in the last quarter, including Kestra Advisory Services LLC, and First Midwest Bank Trust Division.

How do I buy shares of BioNTech?

Shares of BNTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BioNTech's stock price today?

One share of BNTX stock can currently be purchased for approximately $110.61.

How big of a company is BioNTech?

BioNTech has a market capitalization of $25.03 billion and generates $121.63 million in revenue each year. The company earns $-200,540,000.00 in net income (profit) each year or ($0.95) on an earnings per share basis. BioNTech employs 1,310 workers across the globe.

What is BioNTech's official website?

The official website for BioNTech is www.biontech.de.

How can I contact BioNTech?

BioNTech's mailing address is AN DER GOLDGRUBE 12, MAINZ 2M, 55131. The company can be reached via phone at 49-61-31908-40 or via email at [email protected]

This page was last updated on 1/25/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.